Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes
- PMID: 7516411
- PMCID: PMC2191573
- DOI: 10.1084/jem.180.1.347
Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes
Abstract
Four melanoma proteins, MART-1, gp100, tyrosinase, and tyrosinase-related protein-1 (gp75) were evaluated for recognition by HLA-A2-restricted melanoma-specific cytotoxic T lymphocytes (CTLs) derived from the tumor-infiltrating lymphocytes (TIL) of 10 different patients. 9 of 10 TIL recognized MART-1, 4 recognized gp100 (including 3 that also recognized MART-1), but none of the TIL recognized tyrosinase or gp75. Based on the known HLA-A2.1 peptide binding motifs, 23 peptides from MART-1 were synthesized in an attempt to identify the epitopes recognized by TIL. Three peptides were recognized by TIL when pulsed on T2 target cells. One of the 9-mer peptides, AAGIGILTV, was most effective in sensitizing the T2 cells for TIL lysis. This peptide was recognized by 9 of 10 HLA-A2-restricted melanoma-specific CTLs. Therefore, this peptide appears to be a very common immunogenic epitope for HLA-A2-restricted melanoma-specific TIL and may be useful for the development of immunotherapeutic strategies.
Similar articles
-
Identification of new melanoma epitopes on melanosomal proteins recognized by tumor infiltrating T lymphocytes restricted by HLA-A1, -A2, and -A3 alleles.J Immunol. 1998 Dec 15;161(12):6985-92. J Immunol. 1998. PMID: 9862734
-
Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression.J Immunol. 1995 Apr 15;154(8):3961-8. J Immunol. 1995. PMID: 7706734
-
Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1.J Immunol. 1995 Mar 1;154(5):2257-65. J Immunol. 1995. PMID: 7868898
-
Immunobiology of human melanoma antigens MART-1 and gp100 and their use for immuno-gene therapy.Int Rev Immunol. 1997;14(2-3):173-92. doi: 10.3109/08830189709116851. Int Rev Immunol. 1997. PMID: 9131386 Review.
-
Potential use of T cell receptor genes to modify hematopoietic stem cells for the gene therapy of cancer.Pathol Oncol Res. 1999;5(1):3-15. doi: 10.1053/paor.1999.0003. Pathol Oncol Res. 1999. PMID: 10079371 Review.
Cited by
-
Cytotoxicity of tumor antigen specific human T cells is unimpaired by arginine depletion.PLoS One. 2013 May 23;8(5):e63521. doi: 10.1371/journal.pone.0063521. Print 2013. PLoS One. 2013. PMID: 23717444 Free PMC article.
-
Evaluating deep learning-based melanoma classification using immunohistochemistry and routine histology: A three center study.PLoS One. 2024 Jan 19;19(1):e0297146. doi: 10.1371/journal.pone.0297146. eCollection 2024. PLoS One. 2024. PMID: 38241314 Free PMC article.
-
Substitution analog peptide derived from HER-2 can efficiently induce HER-2-specific, HLA-A24 restricted CTLs.Cancer Immunol Immunother. 2006 Nov;55(11):1358-66. doi: 10.1007/s00262-006-0123-0. Epub 2006 Jan 25. Cancer Immunol Immunother. 2006. PMID: 16435129 Free PMC article.
-
Induction of cellular immunity by immunization with novel hybrid peptides complexed to heat shock protein 70.Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3485-90. doi: 10.1073/pnas.97.7.3485. Proc Natl Acad Sci U S A. 2000. PMID: 10725409 Free PMC article.
-
Facile repurposing of peptide-MHC-restricted antibodies for cancer immunotherapy.Nat Biotechnol. 2023 Jul;41(7):932-943. doi: 10.1038/s41587-022-01567-w. Epub 2023 Jan 2. Nat Biotechnol. 2023. PMID: 36593402 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous